Managing Dyslipidemia for PCPs

CE / CME

Optimizing Cardiovascular Health: Attaining LDL-C Targets Through Comprehensive Therapeutic Approaches—A Primary Care Update

Nurse Practitioners/Nurses: 1.00 Nursing contact hour

Pharmacists: 1.00 contact hour (0.1 CEUs)

Physicians: maximum of 1.00 AMA PRA Category 1 Credit

Released: August 21, 2024

Expiration: August 20, 2027

Activity

Progress
1 2
Course Completed

Introduction

In this module, Rachel M Bond, MD, FCC, discusses emerging treatment options to lower low-density lipoprotein cholesterol (LDL-C) and new targets for managing cholesterol to improve outcomes. The key points discussed in this module are illustrated with thumbnails, which can be enlarged by clicking directly on them.

Clinical Care Options plans to measure the educational impact of this activity. The question will be asked twice: once at the beginning of the activity and then once again after the discussion that informs the best choice. Your response will be aggregated for analysis, and your specific response will not be shared. 

Before continuing with this educational activity, please take a moment to answer the following questions.

For those providing patient care, how many people with hyperlipidemia do you provide care for in a typical week?

A patient is unable to achieve their LDL-C goal on maximally tolerated statin plus ezetimibe therapy and has difficulty adhering to frequent alirocumab injections. Based on the Expert Consensus Decision Pathway, which would be a reasonable alternative to alirocumab?

In which of the following clinical scenarios is Lp(a) screening the most strongly supported by guideline recommendations? A 57-yr-old patient with . . .

A 62-yr-old patient without clinical ASCVD or diabetes takes atorvastatin 10 mg/day. Baseline LDL-C was 175 mg/dL and calculated 10-yr ASCVD risk score was 9.4%. At the patient’s next visit, LDL-C  has improved to 145 mg/dL. Based on guidelines, what next step should be taken?